Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Authors
Keywords
-
Journal
LANCET
Volume 396, Issue 10267, Pages 1979-1993
Publisher
Elsevier BV
Online
2020-11-19
DOI
10.1016/s0140-6736(20)32466-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China
- (2020) Zunyou Wu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years
- (2020) Kristi Williams et al. JOURNAL OF INFECTIOUS DISEASES
- Consensus Summary Report for CEPI/BC March 12-13, 2020 Meeting: Assessment of Risk of Disease Enhancement with COVID-19 Vaccines
- (2020) Paul-Henri Lambert et al. VACCINE
- Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes
- (2020) Shengli Xia et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2020) Feng-Cai Zhu et al. LANCET
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- (2020) Pedro M Folegatti et al. LANCET
- Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial
- (2020) Milagritos D Tapia et al. LANCET INFECTIOUS DISEASES
- ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
- (2020) Neeltje van Doremalen et al. NATURE
- Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
- (2020) Denis Y Logunov et al. LANCET
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
- (2020) Shengli Xia et al. LANCET INFECTIOUS DISEASES
- Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
- (2020) Yanchun Peng et al. NATURE IMMUNOLOGY
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
- (2020) Evan J. Anderson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
- (2020) Cheryl Keech et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults
- (2019) Christopher A. Green et al. JOURNAL OF INFECTION
- A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults
- (2019) Morven Wilkie et al. VACCINE
- Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults
- (2018) L. Coughlan et al. EBioMedicine
- Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines
- (2016) Iain D. Milligan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA
- (2016) Katie Ewer et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity
- (2012) Matthew D. J. Dicks et al. PLoS One
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now